コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 sulted in expression of a hybrid CFHR2-CFHR5 plasma protein.
2 d-glycoprotein (AGP) as a chiral acute phase plasma protein.
3 y hemopexin (Hx), an endogenous heme-binding plasma protein.
4 on of selenium-sulfur bond between p-XSC and plasma protein.
5 to identification of a large number of novel plasma proteins.
6 active fragment production in the absence of plasma proteins.
7 d this might be involved in the retention of plasma proteins.
8 n and degradation along with accumulation of plasma proteins.
9 etition of bile acids with FL for binding to plasma proteins.
10 ng the abundance of 44 out of 45 major human plasma proteins.
11 n blood and are largely free from binding to plasma proteins.
12 strated capillaries, causing a major leak of plasma proteins.
13 premature aquation and binding to essential plasma proteins.
14 mplex mixture obtained by digestion of human plasma proteins.
15 cts with a select group of drusen-associated plasma proteins.
16 ssociated functionally with glycosylation of plasma proteins.
17 d thrombosis through its binding of adhesive plasma proteins.
18 acid-lysine-alanine, which binds to clotted plasma proteins.
19 condition of changing radioligand binding to plasma proteins.
20 ts identified a large number of differential plasma proteins.
21 become sensitive to neutralization by mouse plasma proteins.
22 s, however, increased expression of genes of plasma proteins.
23 ermitting routine quantification of multiple plasma proteins.
24 to cause enhanced glomerular permeability to plasma proteins.
27 Trophoblast-derived pregnancy-associated plasma protein A (PAPPA) is specifically elevated in pre
29 to investigate whether pregnancy-associated plasma protein-A (PAPP-A) is useful for risk assessment
30 ncin metalloproteinase, pregnancy-associated plasma protein-A (PAPP-A), which modulates insulin-like
34 distribution, charge, coating molecules, and plasma protein adsorption) that can be effectively tuned
35 o investigate how a systemic absence of this plasma protein affects leukocyte recruitment in alveolit
36 NP) to increase vascular permeability to the plasma protein albumin after an acute plasma volume expa
37 ides and tryptic peptides derived from human plasma proteins, allowing precursor ion selection and CI
38 h by mass spectrometry was identified as the plasma protein alpha1-microglobulin, an established mega
39 ly, we quantified urinary excretion of blood plasma proteins alpha1-microglobulin, albumin, and IgG.
41 ecule (Evans blue dye) that is known to bind plasma proteins, an exogenous protein (tetanus toxin fra
48 1-2% (v/v) 1-butanol mobile phase to remove plasma proteins and concentrate the analytes at the colu
52 l tool for the unbiased in-depth analysis of plasma proteins and may advance biomarker discovery, as
56 altered fucosylation of N-linked glycans on plasma proteins and that glycan biomarkers could improve
63 with many human diseases, only a handful of plasma proteins are routinely used in clinical tests.
64 we sought to identify coordinated changes in plasma proteins associated with breast cancer based on l
66 tibody prevents mural cell loss and modifies plasma proteins associated with Notch3 activity, includi
67 light mass spectrometry was used to identify plasma proteins associated with renal allograft rejectio
68 ibodies are shown to be directed against the plasma protein beta(2)-glycoprotein I and not against ph
69 oth values were significantly lower than the plasma protein binding (71% +/- 5%) and red cell uptake
70 ere significantly lower (P < 0.001) than the plasma protein binding (75% +/- 3%) and red cell uptake
74 n log D, solubility, in vitro clearance, and plasma protein binding also hold in transformation space
75 ng oligonucleotides (MTOs) provide increased plasma protein binding and biodistribution to liver, and
76 ctive starting point, (b) the probability of plasma protein binding and cytotoxicity are often increa
80 vations are presented to illustrate that low plasma protein binding does not necessarily lead to high
82 o metabolic stability, plasma stability, and plasma protein binding for a representative set of compo
84 nges for drug development have been the high plasma protein binding of lead structures, interspecies
87 4, aqueous kinetic solubility, and estimated plasma protein binding values in ranges predictive of go
89 ro studies show that 2d, 2h, and 2j have low plasma protein binding, a necessary condition for renal
90 ed high kidney extraction and excretion, low plasma protein binding, and high metabolic stability as
91 hat aqueous solubility, Caco-2 permeability, plasma protein binding, human ether-a-go-go-related pota
97 alian cell lines was reduced, solubility and plasma-protein binding were improved while retaining pot
100 stments, and efforts, the ongoing search for plasma protein biomarkers for disease so far has come up
101 appointing state of affairs may suggest that plasma protein biomarkers have little more to offer for
102 rs, including hepatic transcription factors, plasma proteins, biotransformation enzymes, and metaboli
105 ntify and quantify AGE modification sites in plasma proteins by reversed phase HPLC mass spectrometry
106 peripheral nervous system are shielded from plasma proteins by the blood-brain barrier and blood-ner
108 performed a genome-wide association scan for plasma protein C antigen concentration with approximatel
109 n's substrate specificity toward cleavage of plasma protein C into activated protein C (APC), which o
112 ace were significantly associated with lower plasma protein carbonyl levels in unaffected sisters.
113 in humans was quantified by measuring blood plasma protein carbonyls using the two commercially avai
115 lore factors that contribute to variation in plasma protein carbonyls, and to determine whether this
116 ients with organic acidemias showed elevated plasma protein carbonyls, while plasma samples from all
117 e, it engages a tightly regulated network of plasma proteins, cell surface receptors, and regulators.
118 ted with early AD pathology by investigating plasma protein changes at the asymptomatic and symptomat
124 There was a significant reduction in total plasma protein concentration after plasmapheresis (p < .
126 ontaneous breathing trial-induced changes in plasma protein concentration, 0.96 (0.90-1.01) for chang
128 s has been shown to be more dependent on the plasma protein concentrations and the type of zeolites t
129 tor, assessed with the median cutoff method, plasma protein concentrations were also not associated w
131 ar lung water indexed for ideal body weight, plasma protein concentrations, hemoglobin concentration,
135 ies showed that the complexes consisted of a plasma protein covalently bound to C3b in a 1:1 molar ra
137 ght to be the transcellular pathway by which plasma proteins cross normal capillary endothelium, but,
138 ur mouse brain vasculome with representative plasma protein databases demonstrated significant overla
139 though the concentrations of most individual plasma proteins decreased, as did the white blood cell t
141 wledge, this marks the lowest LOD for a real plasma protein detection based on label-free LSPR shift
146 M detection of seven out of eight endogenous plasma proteins expressed at ng/mL or subng/mL levels in
147 me or anticipate clinical trajectories using plasma protein expression would allow personalization of
148 ood-brain barrier breakdown characterized by plasma protein extravasation following fibrinogen and Ig
150 ascade is triggered by the activation of the plasma protein factor XII (FXII) and leads to kallikrein
151 ficial surfaces and biologic substances, the plasma proteins factor XII (FXII) and prekallikrein unde
152 n of P. aeruginosa that binds the four human plasma proteins, Factor H, Factor H-like protein-1 (FHL-
153 s thrombin-catalyzed conversion of a soluble plasma protein, fibrinogen, into a polymeric fibrin clot
154 lin loss or paralysis onset and that, of the plasma proteins, fibrinogen specifically induces rapid a
155 erived hepatocytes produced and secreted the plasma proteins, fibrinogen, fibronectin, transthyretin,
157 ureus had sufficiently high solubility, high plasma protein free fraction, and favorable pharmacokine
158 gram increased the fraction unbound to human plasma protein from below minimum detection levels, i.e.
160 paration and rapid measurement of a panel of plasma proteins from quantities of whole blood as small
162 Treatment with the naturally occurring human plasma proteins haptoglobin or hemopexin may have benefi
166 ycoprotein (HRG) is a 75-kDa heparin-binding plasma protein implicated in the regulation of tumor gro
167 of a comparison of the quantification of 100 plasma proteins in >1500 LC-MS runs, the SD range of the
169 We performed multianalyte profiling of 50 plasma proteins in 28 patients with persistent HCV infec
170 iologic hemostasis upon injury involves many plasma proteins in a well-regulated cascade of proteolyt
172 h by serving as a comprehensive reference of plasma proteins in humans and accelerate biomarker disco
186 lized platelets in the presence of exogenous plasma proteins, in comparison with suspension-grown cel
187 luenced by interaction of the particles with plasma proteins, including coagulation factor X (FX), wh
188 mass spectrometry (MS) targeted detection of plasma proteins, including post-translational modificati
189 he circulating thyroid hormones are bound to plasma proteins, including three major thyroid hormone-b
192 stinal digestion, intestinal permeation, and plasma protein interaction of polyphenols from a single
193 vitro bioaccessibility, bioavailability and plasma protein interaction of polyphenols from Annurca a
195 arrier function that restricts flow of large plasma proteins into tissues while allowing small molecu
198 glass-based microarray, able to measure >600 plasma proteins involved in cell-to-cell communication,
199 dema or formation of a pseudocyst containing plasma proteins is a prominent characteristic of nasal p
200 igation of chiral interactions of drugs with plasma proteins is of fundamental importance for drug ef
201 C-reactive protein (CRP), an acute-phase plasma protein, is a major component of inflammatory rea
206 loci explained up to 66% of interindividual plasma protein-level variation and, on average, accounte
207 with cell-type-specific gene expression and plasma protein levels sheds light on potential disease m
208 ithin a gene were analyzed for corresponding plasma protein levels using genome-wide association stud
210 as performed, to evaluate the association of plasma protein levels with dopaminergic system integrity
214 ecovery of body weight, reduced glycosylated plasma proteins levels, and long-term survival without s
216 fic for C5a, suggesting that this ubiquitous plasma protein may have a more significant role in neutr
217 ween platelet glycoprotein (Gp) IIb/IIIa and plasma proteins mediate platelet cross-linking in arteri
218 ed studies of 3 include its binding to human plasma proteins, metabolic stability using human liver m
222 io (a test showing relative amounts of major plasma proteins) of 0.92 (reference range, 0.8-2.0), a u
223 in a mean 70% reduction in circulating PCSK9 plasma protein (p<0.0001) and a mean 40% reduction in LD
224 ysiologic conditions, significant amounts of plasma protein pass the renal filter and are reabsorbed
225 the present study, we report that the inert plasma protein plasminogen (plg) acts as a key regulator
230 tion of genetic variants affecting the human plasma protein profile by combining high-throughput and
231 l-to-cell communication, was used to measure plasma protein profiles in 96 HIV-infected, treatment-na
237 -feet from cerebral microvessels, leakage of plasma proteins, reduction in expression of endothelial
240 Western ligand blot analyses of vitreous and plasma proteins separated by two-dimensional gel electro
243 differentiation is strongly inhibited by the plasma protein serum amyloid P (SAP), and healthy tissue
246 aminase-specific labeling to identify FXIIIa plasma protein substrates and their reactive residues.
248 d protein-1 (MAP-1) is a recently discovered plasma protein that acts as an upstream inhibitor of the
249 ding protein (C4BP), a complement regulatory plasma protein that attenuates the classical and lectin
252 Serum amyloid A (SAA) is an acute-phase plasma protein that functions in innate immunity and lip
254 von Willebrand factor (VWF) is a multimeric plasma protein that mediates platelet adhesion to sites
255 on of iron from transferrin, the circulating plasma protein that normally delivers iron to cells by r
257 a receptor for vitronectin (Vn), an abundant plasma protein that regulates the terminal pathway of th
258 ase-3 (GPx-3) is a selenocysteine-containing plasma protein that scavenges reactive oxygen species in
261 means of identifying preclinical changes in plasma proteins that are potentially relevant to the ear
262 m of this study was to identify and validate plasma proteins that are predictive of outcome in IPF.
263 ue to the blocking of radioligand binding to plasma proteins that elevated the free fractions of the
265 cquisition, assimilation and/or recycling of plasma proteins that predicted overwinter survival.
267 was a significant increase in the number of plasma proteins that were related to endocrine system di
268 0183) site-specific changes in the number of plasma proteins that were related to tumor formation, re
269 profiling of a larger portion of circulating plasma proteins (the plasma proteome) will provide oppor
270 o bind, absorb, and load their granules with plasma proteins, this report is one of the first to expl
271 How fibronectin (FN) converts from a compact plasma protein to a fibrillar component of extracellular
272 a list of proteins or peptides against known plasma proteins to assess novelty of their data set.
274 oss-talk couples transendothelial leakage of plasma proteins to the cytokine circuitry that coordinat
275 ssed mature liver genes such as cytochromes, plasma proteins, transporters, and other hepatic enzymes
277 studies, creating a reference dataset of 496 plasma protein turnover rates from 4 healthy adults.
278 This study is the first to measure global plasma protein turnover rates in rats in vivo, measure v
279 le is known about how concentrations of many plasma proteins vary between individuals from different
280 es the blood flow through its binding to the plasma protein von Willebrand factor (VWF) and transmits
285 ween groups, and biochemical profiling of 40 plasma proteins was performed to identify proteins that
286 the MudPIT-SRM approach to profile abundant plasma proteins, we demonstrated mean increases in peak
287 ng the corresponding effects on inflammatory plasma proteins, we identified cathepsin S as a lead ind
291 tabolic enzymes, some myofibrillar and blood plasma proteins were identified, which were characterise
294 shing the binding affinity between drugs and plasma proteins, which is a critical factor to develop e
295 ted to improve the fraction unbound to human plasma protein while retaining biochemical potency.
298 , and turnover rates were quantified for 157 plasma proteins with half-lives ranging 0.3-103 days.
299 poproteins, 135 lipid species, and 211 other plasma proteins with incident CVD (91 events), defined a
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。